analysis report, page-5

Eddison having significant research resources and a credible brand (in 30 March note) say the following:

Mesoblast’s share price has come down from its highs over the past year despite pipeline progression (two products have moved into pivotal Phase III trials).
and;
" With no clear rationale for the shares languishing, we cite key upcoming potential catalysts that could allow for share price inflections. These include approval of MSC-100-IV for aGvHD in Japan (2015), interim analysis of the current Phase III trial in CHF (H115) and Phase II data for MPC-300-IV in both diabetic kidney disease (H115) and rheumatoid arthritis (H215) ".

My Question : What is Eddison implying ? Yes - in my view its the known unknowns.
(Note: Eddison have increased the valuation).


And morning Stars Kris Kalos says:
“we believe the market is underestimating the partnering prospects for Mesoblast given its late-stage pipeline and is overly focused on the 18-month cash runway”,
This analyst values MSB at $7.00 (middle level when rating All the analysts).

My point is the fundamentals havent changed - other than to have significantly progressed and developed the science - particularly in the last 12 months’.
In my opinion only an eventful Quarter coming up.

Please DYOR.
GLTAH - 2015